Compounds and compositions comprising them are provided. The compounds and compositions are useful for inhibiting transport of heme across membranes in parasitic heme auxotrophic organisms, thereby limiting their growth or killing the parasites.

Compounds and compositions comprising them are provided. The compounds and compositions are useful for inhibiting transport of heme across membranes in parasitic heme auxotrophic organisms, thereby limiting their growth or killing the parasites.

Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.

##STR00001##

Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.

##STR00001##

Disclosed are compounds of formula (I): ##STR00001##
and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

Disclosed are compounds of formula (I): ##STR00001##
and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders. ##STR00001##

Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders. ##STR00001##

The present invention provides a purification method for citalopram or S-citalopram or salts thereof, comprising the following steps: using a washing solution to treat a solution consisting of citalopram and a water-immiscible organic solvent and carrying out separation to obtain an organic layer containing citalopram, or using a washing solution to treat a solution consisting of S-citalopram and a water-immiscible organic solvent and carrying out separation to obtain an organic layer containing S-citalopram; and then, taking the organic layer and carrying out further separation to obtain citalopram or S-citalopram, or adding acid to form a salt and carrying out further separation to obtain an acid salt of citalopram or S-citalopram. The purification method provided by the present invention is simple in operation and high in impurity removal rate.

Provided herein is a method for preparing an Escitalopram bis-hydroxynaphtoate ((S)-(+)-1-(3-(-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-5-cyanisob enzofuranone) crystal form A. Said method is ecofriendly and non pollutive, and the obtained Escitalopram bis-hydroxynaphtoate crystal form A is highly pure and easy to reproduce.